Cannabis and Polysubstance Use: Response Inhibition and Stress Exposure
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Change in incidence of adverse events of cannabinoids across conditions
研究概览
简要总结
The purpose of this Phase I non-therapeutic trial is to examine the neurological effects of cannabis on stress reactivity and inhibition in healthy cannabis users. We expect differences between high ratio CBD:THC cannabis oil, low ratio CBD:THC cannabis oil, and/or placebo on outcome measures.
详细描述
Purpose: To examine the neurological effects of cannabis on stress reactivity and inhibition in healthy adults using recreational cannabis. This is a phase I/pilot healthy subjects trial.
Primary Hypotheses:
- The intervention will be feasible to implement
- Cannabis oil will attenuate stress, measured via biological and self-report data, including salivary molecules, functional Magnetic Resonance Imaging, and standardized psychosocial assessments.
Justification: Current cannabis research focuses on medical uses for cannabis, clinical populations and/or non-commercially available products. There remains limited experimental research on the effects of commercial products in non-clinical regular users of cannabis. Further, most drug use research excludes polysubstance users. Given the high number of people using cannabis to cope with stress, biological evidence is needed to determine the validity of this claim. Stress is known to negatively impact daily functioning and has been linked to poorer mental and physical health outcomes. The effects of cannabinoids on cognitive functioning also have implications for daily functioning.
Objectives: Determine a causal link between commercially available cannabinoid products and mechanisms involved with stress response in polysubstance users, specifically weekly cannabis users with heavy drinking (males: minimum 5 drinks, females: minimum 4 drinks on at least one occasional per month for the past 12 months). Examine the short-term effects of cannabinoids on sleep quality in this population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
盲法说明
Double-blinded masking.
入排标准
- 年龄范围
- 19 Years 至 35 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Are 19-35 years old at the start of the study
- •Have used oral cannabis, including at least 5mg of THC, at least once in their life
- •Have used cannabis at least once in the past year
- •Used cannabis less than 3 times per week on average, in the past 3 months
- •Are using an effective and/or highly effective method of contraception and will continue to do so for the duration of participation in the study. Health Canada's definition of effective methods of contraception include barrier methods of contraception (e.g. male condom, female condom, cervical cap, diaphragm, contraceptive sponge). Health Canada's definition of highly effective methods of contraception includes hormonal contraceptives (e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device (IUD) or intrauterine system (IUS); vasectomy and tubal ligation.
- •Females: are not undergoing alternative fertility methods, such as IVF, or otherwise trying to start a family for the duration of participation
- •Males: will not be donating sperm at some point during the duration of participation
- •Are able to provide informed consent
- •Are able to complete assessments in English
- •Are able to attend sessions according to the study schedule
- •Will provide proof of 2 doses of an approved COVID-19 vaccination
排除标准
- •Are left-handed or ambidextrous
- •Females: are pregnant, nursing, or not on safe pregnancy protection
- •Are trying to conceive
- •Have a known or suspected allergy to cannabinoids and/or palm/coconut oil
- •Are hypersensitive to CBD and/or THC and/or have ever had an adverse reaction (an unwanted and unexpected reaction), to less than 40mg of CBD and/or 10mg THC
- •Have had an adverse reaction (unwanted, unexpected reaction or symptoms) to cannabis within last 6 months
- •Have a major physical problem/health concern, including:
- •Liver-cirrhosis or other liver disease
- •Chronic illness that may increase risk for adverse reactions to cannabis
- •Chronic pain
- •Genetic glucuronidation disorders (e.g., Gilbert's disease)
- •Cardiovascular disease, including ischemic heart disease with unstable angina or recent acute coronary syndrome in the last 3 months, uncontrolled arrhythmias, poorly controlled hypertension or high blood pressure (e.g., 130/80), or severe heart failure
- •Delirium: active delirium or recent delirium < 7 days, or at significant risk of delirium due to multiple comorbidities (e.g., very elderly, cognitive impairment, cerebrovascular disease) and contributing drugs (e.g., alcohol, stimulants, high doses of benzodiazepines, opioid, sedatives, psychoactive medications)
- •Are taking any of the following medications:
- •Any medication that impacts the central nervous system, brain, and/or metabolic system
- •Psychotropic medications, sedatives, and central nervous system depressants, including sleeping pills, tranquilizers, some pain medications, some allergy and cold medications, and anti-seizure medications
- •Medications otherwise affecting the central nervous system, including amphetamines and other sympathomimetics
- •Allergy medications (antihistamines; within 24 hours)
- •Heart medications
- •Blood pressure medication
- •Steroid medications
- •Opioids or other pain medications
- •Anticholinergics: drugs that block acetylcholine, a chemical signal that plays a role in memory and learning.
- •Drugs metabolized by cytochrome P450 enzymes, including amitriptyline, fentanyl, sufentanil, and alfentanil
- •Highly protein-bound drugs, including warfarin, cyclosporine, and amphtericin
- •Drugs metabolized by UGT enzymes, including propofol, antivirals
- •Antiretroviral drugs
- •Stomach acid inhibitors
- •Antibiotics and antifungal medications
- •Heart medications
- •Other medications/substances interfering with CYP2C19 receptors
- •i. Inhibitors: Fluvoxamine, isoniazid (INH), ritonavir ii. Inducers: Carbamazepine, phenytoin, rifampin iii. Substrates: Omeprazole (Prilosec), phenobarbital, phenytoin r. Other medications/substances interfering with CYP3A4 receptors: i. Inhibitors: Clarithromycin (Biaxin), diltiazem (Cardizem), erythromycin, grapefruit juice, itraconazole (Sporanox), ketoconazole (Nizoral), nefazodone (Serzone), ritonavir, telithromycin (Ketek), verapamil (Calan) ii. Inducers: Carbamazepine, Hypericum perforatum (St. John's wort), phenobarbital, phenytoin, rifampin iii. Substrates: Alprazolam (Xanax), amlodipine (Norvasc), atorvastatin (Lipitor), cyclosporine (Sandimmune), diazepam (Valium), estradiol (Estrace), simvastatin (Zocor), sildenafil (Viagra), verapamil, zolpidem (Ambien)
- •Other MRI contraindications (conditions that make MRI procedure inadvisable):
- •a. Have implanted metal clips or wires, including: i. Implanted electronic device (e.g., pacemaker, defibrillator implanted medication infusion pump, electrical stimulator, and/or ear or eye implant) including retained wires that has been removed (e.g., pacemaker wires not attached to a pacemaker) ii. Stainless steel intrauterine device (IUD) iii. Metal in eye or orbit, or metal slivers iv. Ferromagnetic aneurysm clip v. Coil, catheter, or filter in any blood vessel vi. Orthopedic hardware (artificial joint, plate, screw, rod) vii. Shrapnel, bullets, or other metal fragments (i.e., metal in eye or orbit) viii. Artificial heart valve ix. Ear or eye implant x. Brain aneurysm clip xi. Implanted electronic device (i.e., drug infusion pump, electrical stimulator) xii. Coil, catheter, or filter in any blood vessel xiii. Surgery, medical procedure or tattoos (including tattooed eyeliner) in the last six weeks xiv. Other metallic prostheses b. Have a personal or family history of seizures c. Have any significant neurological disorder including, but not limited to: i. Any condition likely to be associated with increased intracranial pressure ii. Space-occupying brain lesion iii. Seizure iv. Cerebral aneurysm v. Parkinson's disease vi. Huntington's chorea vii. Multiple sclerosis viii. Significant head trauma with loss of consciousness for greater than or equal to 5 minutes d. Claustrophobia (i.e., feel uncomfortable in small spaces) or fear of loud, repetitive sounds, or inability to lay still. Participants will have to lie still in the confined space of the MRI scanner.
- •Work nightshifts
- •Have any diagnosed sleep disorders
- •Have dyscalculia
- •Have a neurodevelopmental disorder or cognitive impairments, including:
- •Autism Spectrum Disorder
- •Attention Deficit/Hyperactivity Disorder (ADHD)
- •Have schizophrenia spectrum disorder and/or history of psychosis
- •Meet criteria for potential mental health disorder in the Mini International Neuropsychiatric Interview (M.I.N.I.) Screen Version 7.0.2, except for alcohol and cannabis use disorders
- •Any diagnosed current mental health disorder and/or diagnosis of a mental health disorder within the past year
- •Have a non-correctable clinically significant sensory impairment (e.g., cannot hear well enough to cooperate with interview)
- •19) Are unable to attend sessions according to the study schedule 20) Have used opiates more than twice in the past 30 days
研究组 & 干预措施
Cannabis oil with a high ratio of THC to CBD
Participants will be given a single dose of oral cannabis oil containing 5mg THC and 0.17mg CBD.
干预措施: Cannabis oil with a high ratio of THC to CBD (Drug)
Cannabis oil with a high ratio of CBD to THC
Participants will be given a single dose of oral cannabis oil containing 5mg THC and 25mg CBD.
干预措施: Cannabis oil with a high ratio of CBD to THC (Drug)
Placebo
Participants will be given a single dose of 1 mL placebo (carrier oil with botanical terpenes) via oral route of administration.
干预措施: Placebo (Drug)
结局指标
主要结局
Change in incidence of adverse events of cannabinoids across conditions
时间窗: 5 weeks
Assessed through self-reports from study participants (semi-structured interviews) and clinically significant adverse changes in vital signs (heart rate, blood pressure).
Change in stress response across conditions
时间窗: 5 weeks
Indicated by differences in blood-oxygenation-level-imaging (BOLD) response via functional magnetic resonance imaging (fMRI), salivary stress molecule levels (eg cortisol, IgA), heart rate, and self-reports. Participants will fill out a daily diary each morning starting the day after session 1 until the day of session 5 with their self-reports.
Protocol feasibility
时间窗: Through study completion; average of 1 year
Measured via means and rates of study recruitment
Procedure feasibility
时间窗: Through study completion; average of 1 year
Measured via means and rates of study recruitment
次要结局
- Change in sleep quality across conditions(5 weeks)
- Change in subjective response to cannabis(5 weeks)
- Change in psychological distress across conditions(5 weeks)
- Change in state anxiety across conditions(5 weeks)
- Change in performance on behavioral impulsivity tasks across conditions(5 weeks)
研究者
Christian Schutz
Associate Professor
University of British Columbia